Sacituzumab Tirumotecan (Sac-TMT/MK-2870/SKB264): A Novel Antibody–Drug Conjugate in Breast Cancer

Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264) is a novel antibody-drug conjugate (ADC) targeting TROP2, showing promise in breast cancer treatment by delivering a belotecan-derived topoisomerase I inhibitor. Clinical trials have demonstrated improved overall response, disease control rates, and progression-free survival. The safety profile is manageable, with common adverse events being grade 1/2 nausea and alopecia, and more severe grade 3/4 neutropenia, leukopenia, and stomatitis, but no treatment-related deaths. Sac-TMT represents a promising new option for diverse breast cancer populations with a manageable toxicity profile.